scholarly journals A Case of Primary Adenocarcinoma of Aberrant Pancreas in the Stomach Identified from Pyloric Stenosis and Accompanied by Lymph Node Metastasis of the Posterior Pancreatic Head

2015 ◽  
Vol 76 (7) ◽  
pp. 1772-1776
Author(s):  
Shuichi SAKAMOTO ◽  
Toshikazu KIMURA ◽  
Futoshi UNO ◽  
Takaomi TAKAHATA ◽  
Masanobu MARUYAMA ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Pyloric Stenosis ◽  
Pancreatic Head ◽  
Primary Adenocarcinoma ◽  
Node Metastasis ◽  
Aberrant Pancreas

Nup88 Expression in Normal Mucosa, Adenoma, Primary Adenocarcinoma and Lymph Node Metastasis in the Colorectum

Tumor Biology ◽  
2007 ◽  
Vol 28 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Zhi-Yong Zhang ◽  
Zeng-Ren Zhao ◽  
Li Jiang ◽  
Jia-Chen Li ◽  
Yan-Min Gao ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Normal Mucosa ◽  
Primary Adenocarcinoma ◽  
Node Metastasis

Peripyloric Lymph Node Metastasis Is a Rare Condition in Carcinoma of the Pancreatic Head

Pancreas ◽  
2005 ◽  
Vol 31 (1) ◽  
pp. 88-92 ◽  
Author(s):  
Berthold Gerdes ◽  
Annette Ramaswamy ◽  
Detlef K Bartsch ◽  
Matthias Rothmund
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Pancreatic Head ◽  
Rare Condition ◽  
Node Metastasis

scholarly journals Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection

2021 ◽  
Vol 11 ◽  
Author(s):  
Jiazhang Xing ◽  
Bo Yang ◽  
Xiaorong Hou ◽  
Ning Jia ◽  
Xiaolei Gong ◽  
...  
Keyword(s):  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Lymph Node Metastasis ◽  
Cox Regression ◽  
Pancreatic Head ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Adjuvant Chemoradiation ◽  
Node Metastasis ◽  
R1 Resection

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a poor prognosis. In resectable PDAC, the recurrence rate is still high even when surgery and adjuvant chemotherapy (CT) are applied. Regional lymph node metastasis and positive margins are associated with higher recurrence risk and worse survival. Adjuvant radiotherapy has been explored, but its efficacy remains controversial. In recent years, some characteristics have been reported to stratify patients who may benefit from adjuvant chemoradiation (CRT), such as lymph node metastasis and margin status. Adjuvant chemotherapy followed by chemoradiation (CT-CRT) was also proposed. A total of 266 patients with resectable PDAC who have lymph node metastasis or R1 resection after surgery were enrolled. In multivariate Cox regression analyses, pancreatic body or tail tumor location (HR 0.433, p<0.0001, compared with pancreatic head) and adjuvant CT predicted a better survival, while there were no significant differences among the different CT regimens. Higher T stage indicated poor survival (stage I: reference; stage II: HR 2.178, p=0.014; stage III: HR 3.581, p=0.001). Propensity score matching was applied in 122 patients to explore the role of CRT. A cohort of 51 patients (31 and 20 patients in the CT and CT-CRT groups, respectively) was generated by matching. Further analyses revealed adjuvant CT-CRT was associated with prolonged survival compared with CT alone (HR 0.284, p=0.014) and less frequent local recurrences (56.5% vs. 21.4% in the CT and CT-CRT group, respectively). However, no significant differences in disease-free survival among these two groups were observed.

Evaluation of the Site and Frequency of Lymph Node Metastasis with Non-Functioning Pancreatic Neuroendocrine Tumor

2019 ◽  
Vol 60 (5-6) ◽  
pp. 219-228
Author(s):  
Wataru Izumo ◽  
Ryota Higuchi ◽  
Toru Furukawa ◽  
Takehisa Yazawa ◽  
Shuichiro Uemura ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lymph Node Dissection ◽  
Neuroendocrine Tumors ◽  
Pancreatic Head ◽  
Disease Free Survival ◽  
Pancreatic Neuroendocrine Tumors ◽  
Node Dissection ◽  
Free Survival ◽  
Node Metastasis

Backgrounds: The optimal lymph node dissection range in patients with non-functioning pancreatic neuroendocrine tumors is not yet clear. In this study, we investigated the site and frequency of lymph node metastasis and the significance of lymph node dissection in patients with non-functioning pancreatic neuroendocrine tumors. Methods: This retrospective study analyzed 74 patients who underwent a curative pancreatectomy for non-functioning pancreatic neuroendocrine tumors between 2000 and 2016. The site and frequency of lymph node metastasis and clinicopathological factors were evaluated. Results: The rate of synchronous lymph node metastasis was 17.6%, with 11.1 and 29.4% for tumors with diameters of 10–19 mm and ≥20 mm, respectively. Lymph node metastasis was not observed for tumors with a diameter <10 mm. Lymph node metastasis was observed along the anterior (17a: 13.3%, 17b: 12.5%) and posterior (13a: 5.9%, 13b: 26.7%) surfaces of the pancreatic head and the superior mesenteric artery (14p: 12.5%, 14d: 7.7%) in patients with non-functioning pancreatic head neuroendocrine tumors, in the common hepatic (8a: 5.3%), splenic (10: 14.3%, 11p: 17.6%, 11d: 12.5%), and super mesenteric artery (14d: 14.3%) in patients with non-functioning pancreatic body neuroendocrine tumors, and only in the splenic artery (11p: 8.3%, 11d: 7.7%) in patients with non-functioning pancreatic tail neuroendocrine tumors. Grade 2 (HR = 6.21) and synchronous lymph node metastasis (HR = 10.4) were significant risk factors for disease-free survival. The 5-year disease-free survival was 95.7, 72.6, and 0% in patients with 0, 1, and 2 prognostic factors, respectively. Conclusions: This study clarified the site and frequency of lymph node metastasis and the optimal range of lymph node dissection in patients with non-functioning pancreatic neuroendocrine tumors.

scholarly journals Evaluation of D2-plus radical resection for gastric cancer with pyloric invasion

BMC Surgery ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhi-yuan Xu ◽  
Can Hu ◽  
Shangqi Chen ◽  
Yi-an Du ◽  
Ling Huang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lymph Nodes ◽  
Survival Benefit ◽  
Pancreatic Head ◽  
Radical Resection ◽  
Radical Gastrectomy ◽  
Node Metastasis ◽  
Link Type

Abstract Background The optimal lymphadenectomy for gastric cancer (GC) with pyloric invasion is controversial because the pattern of lymph node metastasis is different from that of distal GC. The rate of lymph node metastasis into the posterior area of the pancreatic head and hepatoduodenal ligament is high. This study evaluated the estimated benefit of radical gastrectomy with D2-plus lymphadenectomy in patients with pyloric invasion. Methods All patients with GC invading the pylorus who underwent curative surgical resection with D2-plus lymphadenectomy between February 2013 and September 2015 were enrolled in the study. The index of estimated benefit from lymph node dissection (IEBLD) was calculated by multiplying the incidence of metastasis to each lymph node station by the 3-year overall survival (OS) rate of patients with metastasis to that station. Results In total, 128 patients were eligible. The rate of lymph node metastasis and the 3-year OS rate (and IEBLD) of the patients with metastasis to lymph nodes were 14.3 and 44.4% (5.56) for No. 8p, 10.9 and 35.7% (3.89) for No. 12b, 9.5 and 33.3% (3.13) for No. 12p, 18.8 and 54.2% (10.19) for No. 13, and 21.8 and 53.6% (11.68) for No. 14v, respectively. Conclusions In radical gastrectomy for GC with pyloric invasion, some survival benefit was observed with dissection of the No. 13 and No. 14 lymph nodes, but there was no survival benefit with dissection of the No. 8p lymph nodes. The No. 12b and No. 12p lymph nodes may be better to dissect in cT3 GC patients with pyloric invasion. Trial registration http://ClinicalTrials.gov Identifier: NCT01836991. Date of registration: April 17, 2013.

Sign in / Sign up

Export Citation Format

Share Document